GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Hanmi Science Co Ltd (XKRX:008930) » Definitions » Debt-to-EBITDA

Hanmi Science Co (XKRX:008930) Debt-to-EBITDA : 1.09 (As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Hanmi Science Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hanmi Science Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩202,967 Mil. Hanmi Science Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩10,769 Mil. Hanmi Science Co's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩197,080 Mil. Hanmi Science Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Hanmi Science Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:008930' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.17   Med: 1.05   Max: 3.05
Current: 1.43

During the past 13 years, the highest Debt-to-EBITDA Ratio of Hanmi Science Co was 3.05. The lowest was 0.17. And the median was 1.05.

XKRX:008930's Debt-to-EBITDA is ranked better than
54.67% of 75 companies
in the Medical Distribution industry
Industry Median: 1.87 vs XKRX:008930: 1.43

Hanmi Science Co Debt-to-EBITDA Historical Data

The historical data trend for Hanmi Science Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanmi Science Co Debt-to-EBITDA Chart

Hanmi Science Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 1.36 1.01 2.45 1.43

Hanmi Science Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.93 1.47 1.68 1.26 1.09

Competitive Comparison of Hanmi Science Co's Debt-to-EBITDA

For the Medical Distribution subindustry, Hanmi Science Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanmi Science Co's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Hanmi Science Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hanmi Science Co's Debt-to-EBITDA falls into.



Hanmi Science Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hanmi Science Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(202967.456 + 10768.617) / 149434.628
=1.43

Hanmi Science Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(202967.456 + 10768.617) / 197080.448
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Hanmi Science Co  (XKRX:008930) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Hanmi Science Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hanmi Science Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanmi Science Co (XKRX:008930) Business Description

Traded in Other Exchanges
N/A
Address
214 Muha-ro Paltan-myeon, Gyeonggi-do, Hwaseong, KOR
Hanmi Science Co Ltd is a Korea-based holding company. The company through its subsidiaries manufactures and distributes pharmaceutical products. The company offers prescription drugs such as neuropathic pain, obesity, epilepsy, lactobacillus intestinal supplement, oral care, hair growth, anti-inflammatory, schizophrenia, smoking cessation aid, diabetes, osteoporosis, antiemetic, vaginal contraceptive, expectorants, ophthalmic, immunosuppressant, prostatism, cancer, antitussives, vitamins and nutritional supplements, constipation, dermatology, among others.

Hanmi Science Co (XKRX:008930) Headlines

No Headlines